Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis

Early intervention with high-efficacy disease-modifying therapy (HE DMT) may be the best strategy to delay irreversible neurological damage and progression of multiple sclerosis (MS). In European healthcare systems, however, patient access to HE DMTs in MS is often restricted to later stages of the...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Journal of neurology Ročník 269; číslo 3; s. 1670 - 1677
Hlavní autoři: Filippi, Massimo, Danesi, Romano, Derfuss, Tobias, Duddy, Martin, Gallo, Paolo, Gold, Ralf, Havrdová, Eva Kubala, Kornek, Barbara, Saccà, Francesco, Tintoré, Mar, Weber, Jörg, Trojano, Maria
Médium: Journal Article
Jazyk:angličtina
Vydáno: Berlin/Heidelberg Springer Berlin Heidelberg 01.03.2022
Springer Nature B.V
Témata:
Consensus
Health care
Humans
Medicine
Medicine & Public Health
Multiple sclerosis
Multiple Sclerosis - drug therapy
Neurology
Neuroradiology
Neurosciences
Patients
Resource allocation
Short
Short Commentary
Healthcare system
High-efficacy disease-modifying therapy
Pharmacoeconomics
Multiple sclerosis
Benefit–risk profile
Unrestricted access
ISSN:0340-5354, 1432-1459, 1432-1459
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Early intervention with high-efficacy disease-modifying therapy (HE DMT) may be the best strategy to delay irreversible neurological damage and progression of multiple sclerosis (MS). In European healthcare systems, however, patient access to HE DMTs in MS is often restricted to later stages of the disease due to restrictions in reimbursement despite broader regulatory labels. Although not every patient should be treated with HE DMTs at the initial stages of the disease, early and unrestricted access to HE DMTs with a positive benefit–risk profile and a reasonable value proposition will provide the freedom of choice for an appropriate treatment based on a shared decision between expert physicians and patients. This will further optimize outcomes and facilitate efficient resource allocation and sustainability in healthcare systems and society.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:0340-5354
1432-1459
1432-1459
DOI:10.1007/s00415-021-10836-8